FDA, Penn get personal
This article was originally published in The Tan Sheet
Executive Summary
Following FDA's Sept. 12 health information advisory regarding melamine-contaminated infant formula from China, the agency says Sept. 23 "there is no known threat of contamination in infant formula manufactured by companies that have met the requirements to sell such products in the United States." While state and local officials collaborating with the agency have not found Chinese formula on store shelves in large Asian enclaves in the U.S., FDA says it is taking "proactive measures" to sample and test other imported milk-derived ingredients and finished food products for Chinese milk proteins (2"The Tan Sheet" Sept. 15, 2008, In Brief)
You may also be interested in...
FDA warns on China formula
Milk-based infant formula manufactured in China may be contaminated with melamine, which raises the protein profile of dairy products and may have contributed to reports of kidney stones in Chinese infants, FDA says Sept. 12. The agency says companies approved for marketing milk-based formula in the U.S. are not importing materials from China, though officials are investigating whether Chinese infant formula is being sold in Asian specialty markets inside the U.S. In its same-day health information advisory, FDA requests the help of states in removing Chinese infant formula products from store shelves. In April 2007, melamine-tainted Chinese pet food caused FDA to issue an import alert on vegetable proteins from China (1"The Tan Sheet" May 21, 2007, p. 6)
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.